TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~(1) stage 3 or 4 meibomian gland dysfunction~Exclusion Criteria:~1. history of previous ocular or intraocular surgery~2. ocular infection, non dry eye ocular inflammation, ocular allergy, autoimmune disease,~3. history of intolerance or hypersensitivity to any component of the study medications,~4. wearing contact lenses during the study period, presence of current punctal occlusion,~5. pregnancy, lactating women, and children.~6. Additionally, patients were excluded if they were using any topical ocular or systemic medication that could be used for the treatment MGD or dry eye, including topical or oral antibiotics, topical cyclosporine A, topical or oral steroids, topical non-steroidal anti-inflammatory drugs, topical ocular allergy medications or artificial tears

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lotemax with warm compress group (Type: EXPERIMENTAL): topical loteprednol etabonate (lotemax 0.5%) qid and warm compress \& ocular massage (a minimum of four times, once or twice a daily) for 2months
- warm compress only group (Type: ACTIVE_COMPARATOR): warm compress only group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed supratentorial anaplastic astrocytoma or glioblastoma~* Age \> 65~* Karnofsky performance score \> 60%~* Neutrophilic granulocyte count \> 1500/µl~* Platelet count \> 100 000/µl~* Hemoglobin \> 10 g/dl~* Serum creatinine \< 1.5 times the lab's upper normal limit~* AST or ALT \< 3 times the lab's upper normal limit~* Alkaline phosphatase \< 3 times the lab's upper normal limit~* No previous systemic chemotherapy~* No previous radiotherapy to the brain~* Written consent~Exclusion Criteria:~* Serious medical or neurological condition with a poor prognosis~* HIV infection~* Second cancer requiring radiotherapy or chemotherapy (contact the study coordinat if necessary)~* Hypersensitivity to temozolomide~* Conditions associated with regular vomiting that might affect oral administration of the drugs~* Psychological, familial, social or geographical circumstances with major implications for compliance with the study visit schedule~* Patient was taking part in other intervention studies within a month of starting this study

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy (Type: ACTIVE_COMPARATOR): 6 weeks standard partial brain treatment.
- Temozolomide (Type: EXPERIMENTAL): Temozolomide in a one week on/one week off schedule per Wick et al. 2004 and A. Wick et al. 2007

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between 2L Coolprep® and Combination of 1L Coolprep® and Bisacodyl as Bowel Preparation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* willing to consent/undergo necessary procedures~* between the age of 20 and 75 years~* healthy persons planning to have a colonoscopy~Exclusion Criteria:~* history of abdominal surgery except appendectomy~* inflammatory bowel disease~* clinically or laboratory-confirmed ileus (both functional and mechanical)~* malignancy~* clinically severe cerebrovascular, cardiovascular, kidney, liver or hematologic disease~* dementia, cognitive impairment~* the use of prokinetics, antispasmodics, antidiarrheal drugs, laxatives or neuroleptics in 2 weeks~* known sensitivity to the agents used~* Pregnancy, Lactating woman

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 2L Coolprep® (Type: ACTIVE_COMPARATOR): None
- 1L Coolprep® and Bisacodyl (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Age ≥ 18 years~* Complete and adequate resection of Stage III melanoma with histologically confirmed melanoma metastatic to lymph node~* Disease-free~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1~* Randomization within 12 weeks of surgery~Exclusion Criteria:~* Prior therapy for melanoma except surgery~* Auto-immune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients, ages 18 years or older who have signed the informed consent~* Has a qualifying skin and skin structure infection~* Female patients must not be pregnant at the time of enrollment~* Must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug~Exclusion Criteria:~* Infections where the outcome is strongly influenced by factors other than protocol-defined treatment and procedures, that require antibacterial treatment for greater than 14 days~* Evidence of significant immunological disease~* Severe sepsis or septic shock~* Has a history of hypersensitivity or allergic reaction to any tetracycline or to linezolid~* Has received an investigational drug within past 30 days~* Women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omadacycline (Type: EXPERIMENTAL): Omadacycline IV; Omadacycline tablets
- Linezolid (Type: ACTIVE_COMPARATOR): Linezolid IV; Linezolid tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients of both sexes (women after menopause, women of child-bearing age after sterilization or if practicing reliable contraception)~* Type 2 DM requiring insulin therapy after failure of maximal oral antidiabetic treatment (glycosylated Hb \> 7.5%) and need for exogenous insulin. (No concomitant use of oral antidiabetic agents)~* Being ambulatory~* Age: 30 to 80 years~* Proven absence of Islet Antibodies, if QI \< 28 kg/m2~* Insulin therapy 4 times daily (21), or insulin therapy 2 times daily using insulin 'mixtures' (rapidly and slowly acting)~* Standard dietary prescription by the dietician~* Absence of keto-acidosis~* Informed consent~Exclusion Criteria:~* Congestive heart failure, NYHA-classes III or IV~* Cardiac failure and/or myocardial infarction in the last four months before enrolment~* Other severe organic / systemic disease~* Metformin-induced lactic-acidosis~* Intolerance to metformin hydrochloride~* Renal disease or renal dysfunction~* Hypoxic states~* Severe hepatic dysfunction~* Excessive alcohol intake, acute or chronic~* Acute or chronic metabolic acidosis

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥40 years with newly or formerly diagnosed moderate to severe COPD (Patients with postbronchodilator FEV1/FVC ratio \<0.70, and FEV1 \<80% of predicted normal. Patients have chronic cough or chronic productive cough with breathlessness even walking slowly along flat ground.) Current smokers or exsmokers with a smoking history of at least 10 pack-years~* Patients who have no exacerbation within last 4 weeks~* Females patients with childbearing potential using effective birth control method~* Patients who has a capability of communicate with investigator~* Patients who accept to comply with the requirements of the protocol~* Patients who signed written informed consent prior to participation~Exclusion Criteria:~* Patients who have history of hypersensitivity to drugs contains long-acting beta2-agonist or corticosteroids~* Patients who have abnormal blood glucose level ((≥140 mg/dl)~* Patients who have unregulated diabetes mellitus~* Patients who have a serum potassium level of ≤3.5 mEq/L or \>5.5mEq/L~* Patients who have asthma~* Patients who have a history of myocardial infarction, severe hearth failure, acute ischemic coroner disease or severe cardiac arrhythmia requiring treatment within least 6 weeks~* Patients who have lung cancer~* Patients vaccinated with live attenuated vaccines within 2 weeks prior to screening visit or during run-in period.~* Patients who had COPD exacerbation or lower respiratory track infections that required antibiotic, oral or parenteral corticosteroid treatment within 4 weeks prior to screening visit or during run-in period.~* Women who are pregnant or nursing~* History of allergic rhinitis or atopy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Formoterol/Budesonide 12/400 mcg Discair (Type: EXPERIMENTAL): Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 18 to 77 years old, with type 2 diabetes and with inadequate glycemic control~* Drug naive or treated with anti-diabetic medication for \< 24 weeks~* C-peptide ≥ 1.0 ng/mL~* Body Mass Index ≤ 45.0 kg/m²~Exclusion Criteria:~* AST and/or ALT \> 3 times ULN~* Serum total bilirubin \> 2 mg/dL~* Serum creatinine ≥ 1.50 mg/dL for men or ≥ 1.40 mg/dL for women~* Creatine kinase ≥ 3 times ULN~* Symptoms of severely uncontrolled diabetes~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): None
- Group 2 (Type: EXPERIMENTAL): None
- Group 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improved Induction and Maintenance Immunosuppression in Kidney Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Primary renal transplant recipient for end-stage renal disease~Exclusion Criteria:~* Recipient age \< 18 years or \> 65 years~* Previous history of CMV disease~* Hepatitis B and C recipients~* Primary disease states that require steroids for immunosuppression~* Re-transplant with immunological cause of renal or pancreas loss~* Non heart beating donors~* Recipient of pediatric en bloc kidneys~* Recipient with a Panel Reactive Antibody (PRA) score \>75%~* Patients who have received 3 or more prior transplants, excluding pancreas~* Patients who are past recipients of other solid organ transplants~* Previous history of BK virus~* Previous treatment with Thymoglobulin~* Allergy to rabbits~* Simultaneous Kidney/Pancreas transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
- Group 2 (Type: EXPERIMENTAL): Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
- Group 3 (Type: EXPERIMENTAL): Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.
- Group 4 (Type: EXPERIMENTAL): Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* OAB patients who present with OAB symptoms(≥8 micturitions and ≥3 urgency episodes per 24 h documented in the baseline bladder diary)~* OAB patients dissatisfied with their prior therapy with tolterodine~Exclusion Criteria:~* Patients with any contraindication to fesoterodine usage, e.g., urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or known hypersensitivity to the drug or its ingredients.~* Patients with significant hepatic and renal disease or other significant unstable diseases.~* OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label-fesoterodine (Type: EXPERIMENTAL): Single treatment study arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than 18 years old,~* Documented HIV-1 seropositive,~* CD4 count greater than 200,~* Not on HIV antiretroviral therapy,~* HSV-2 seropositive as determined by Focus EIA (IN \>3.5)~* Not intending to move out of the area for the duration of study participation.~* Willing and able to:provide independent written informed consent;undergo clinical evaluations;take study drug as directed;adhere to follow-up schedule.~* Bacterial STDs (symptomatic STD syndromes or laboratory-confirmed asymptomatic gonorrhea and syphilis) are treated within two weeks of study enrollment and random assignment.~Exclusion Criteria:~MSM who meet any of the following criteria are not eligible for this study:~* Known history of adverse reaction to valacyclovir, acyclovir or famciclovir;~* Planned open label use of acyclovir, valacyclovir, or famciclovir~* Known medical history of seizures~* Known renal failure, serum creatinine \>2.0mg/dl~* Hematocrit \< 30 %

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Positional Therapy After Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Probable ischemic stroke within prior 14 days~Exclusion Criteria:~* Any medical condition precluding the avoidance of supine posture or dictating the need for a particular position.~* Current use of CPAP (or other PAP), mechanical ventilation, or supplemental oxygen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- positional therapy (Type: EXPERIMENTAL): Avoidance of supine positioning.
- Control (Type: NO_INTERVENTION): Position ad lib.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed AS patients.~  * 18 years old~* Did not receive previous biological treatment for any reason~Exclusion Criteria:~* Patients previously or currently treated with other biological therapies.~* Use of etanercept for less than 1 year duration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with ankylosing spondylitis (Type: None): Iraqi patients diagnosed with ankylosing spondylitis that received Etanercept as treatment for disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven, previously untreated gastric cancer~  * Stage IB, II, III, or IV (T3-4, N0 OR any T, N1-2, M0)~ * No metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* SWOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 4000/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 9 g/dL~Hepatic:~* Bilirubin less than 2 mg/dL~* SGOT/SGPT no greater than 2 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 3 times ULN~* PT, aPTT, and TT normal~* No Gilbert's disease~Renal:~* BUN no greater than 30 mg/dL~* Creatinine no greater than 1.5 mg/dL OR~* Creatinine clearance greater than 60 mL/min~Cardiovascular:~* No myocardial infarction within the past 3 months~* No congestive heart failure requiring therapy~Other:~* No other invasive malignancy in the past 5 years except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix~* No active or uncontrolled infection~* HIV negative~* No other severe concurrent disease~* No psychiatric disorders that would preclude compliance~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy for gastric cancer~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy for gastric cancer~Surgery:~* No prior surgery for gastric cancer~* No emergent need for surgery for gastrointestinal obstruction, perforation, or hemorrhage

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete